uploads///Article

Sanofi’s Segment-Wise Sales by Region

By

Updated

Geographical classification

Sanofi (SNY) products are sold in over 120 countries. The company’s markets are classified into four geographical regions for reporting purposes:

  • Western Europe, excluding net sales of Sanofi Pasteur MSD, a joint venture for human vaccines with Merck and Co. for Europe
  • United States
  • emerging markets
  • The rest of the world, which refers to Japan, Canada, Australia, and New Zealand
Article continues below advertisement

Western Europe

For Western Europe, the contribution of the pharmaceutical segment was ~25.7% of total segment sales at 7.1 billion euros in 2014. The human vaccines segment under Sanofi Pasteur was 5.1% of total segment sales at 204 million euros. The animal health segment, Merial, contributed ~24.2% of total segment sales at 502 million euros.

United States

For the US markets, the contribution of the pharmaceutical segment was ~28.2% of total segment sales at 7.8 billion euros in 2014. The human vaccines segment under Sanofi Pasteur was 47.1% of total segment sales at 1.87 billion euros. The animal health segment, Merial, contributed ~36.0% of total segment sales at 747 million euros.

Article continues below advertisement

Emerging markets

For emerging markets, the contribution of the pharmaceutical segment was ~32.6% of total segment sales at 9.0 billion euros in 2014. The human vaccines segment under Sanofi Pasteur accounted for 33.7% of total segment sales at 1.34 billion euros. The animal health segment, Merial, contributed ~28.3% of total segment sales at 587 million euros.

Rest of the world

For the rest of the world, the contribution of the pharmaceutical segment was ~11.8% of total segment sales at 3.3 billion euros in 2014. The human vaccines segment under Sanofi Pasteur was 7.5% of total segment sales at 299 million euros. The animal health segment, Merial, contributed ~7.2% of total segment sales at 149 million euros.

Other companies like Pfizer (PFE), GlaxoSmithKline (GSK), Bristol-Myers Squibb (BMY), and AstraZeneca (AZN) compete with Sanofi on certain product mixes. The Health Care Select Sector SPDR ETF (XLV) is focused on the pharmaceutical segment.

Advertisement

More From Market Realist